ESPN 51th Annual Meeting

ESPN 2018


 
DOES COMPLEXING OF ALBUMIN WITH HIGH MOLECULAR WEIGHT/LOW NEGATIVELY CHARGED NANOPARTICLES INCREASE HALF-LIFE OF ALBUMIN IN CIRCULATION IN NEPHROTIC SYNDROME?
ALPER SOYLU 1 MERAL TORUN BAYRAM 1 IŞIL SOMALI 2 SALIH KAVUKCU 1

1- DOKUZ EYLUL UNIVERSITY MEDICAL FACULTY, DEPARTMENT OF PEDIATRICS
2- DOKUZ EYLUL UNIVERSITY MEDICAL FACULTY DEPARTMENT OF INTERNAL MEDICINE
 
Introduction:

Proteinuria in nephrotic syndrome has been attributed to loss of size and charge selective barrier function of glomerular basement membrane. We aimed to evaluate if high molecular weight and/or low negatively charged albumin-nanoparticle compounds could be used to increase circulatory half-life of albumin in nephrotic syndrome. For this purpose, we performed a preliminary study with a nanoparticle bound-albumin formulation (Abraxane; a novel formulation of paclitaxel in which paclitaxel is complexed with albumin to form stable, 130 nm particles) in routine clinical use.

Material and methods:

 10 adult patients with pancreas cancer were divided into two groups as those treated with Abraxane (Group 1) and with paclitaxel alone (Group 2). Serum albumin levels at diagnosis and at last visit were compared. In addition, in Group 1, serum albumin levels before and 1-week after Abraxane treatment were compared. 

Results:

In both groups, there were 4 male and 1 female patients. Mean age was similar (63.4±11.3 vs 59.8±12.2 years). Albumin at diagnosis and at last visit did not differ between Groups 1 and 2 (4.04±0.39 vs 3.85±0.30 and 3.20±0.78 vs 3.56±0.81 g/dL, respectively). Furthermore, serum albumin level after 1 week of therapy was significantly lower than the pretreatment level in Group 1 (3.57±0.63 vs 3.85±0.52, p=0.035), probably due to the effect of chemotherapy.

Conclusions:

Serum albumin levels in patients treated with Abraxane were not different from those treated with paclitaxel alone. This could be due to low albumin content of Abraxane (900 mg albumin bound to 100 mg paclitaxel; equivalent to 1,125 g/m2 albumin). This preliminary methodology does neither encourage nor discourage the efforts to develop a formulation of a pharmaceutical compound composed of albumin complexed to high molecular weight and/or low negatively charged nanoparticles with an extended half-life in circulation in nephrotic syndrome.